Histomorphological and inflammatory changes of white adipose tissue in gastrointestinal cancer patients with and without cachexia.
Adipose tissue
Body composition
Cachexia
Cancer
Fibrosis
Inflammation
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
09
11
2021
received:
03
06
2021
accepted:
22
11
2021
pubmed:
24
12
2021
medline:
24
3
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
During cancer cachexia, several alterations occur in peripheral tissues, and the adipose tissue may be involved during the catabolic state. We aimed at investigating histological rearrangement and infiltration of inflammatory cells in subcutaneous adipose tissue (SAT) of patients with cancer undergoing surgery, according to the presence/absence of cachexia. We considered gastrointestinal cancer patients and controls with non-malignant diseases undergoing surgery. We collected SAT samples and performed histomorphological analyses [cross-sectional area (CSA) and per cent of fibrosis] and immunohistochemistry to characterize the inflammatory cells. By computed tomography (CT) scan, we calculated SAT and visceral adipose tissue (VAT). We enrolled 51 participants (31 gastrointestinal cancer patients and 20 controls). In cancer patients, cachexia was present in 13/31 (42%). The CSA (μm We found histological alterations of SAT among gastrointestinal cancer patients and in particular significant changes in CSA, fibrosis, and inflammation when cachexia was present; the changes in histomorphological parameters of the adipocytes reflected alterations in adiposity at body composition analysis.
Sections du résumé
BACKGROUND
During cancer cachexia, several alterations occur in peripheral tissues, and the adipose tissue may be involved during the catabolic state. We aimed at investigating histological rearrangement and infiltration of inflammatory cells in subcutaneous adipose tissue (SAT) of patients with cancer undergoing surgery, according to the presence/absence of cachexia.
METHODS
We considered gastrointestinal cancer patients and controls with non-malignant diseases undergoing surgery. We collected SAT samples and performed histomorphological analyses [cross-sectional area (CSA) and per cent of fibrosis] and immunohistochemistry to characterize the inflammatory cells. By computed tomography (CT) scan, we calculated SAT and visceral adipose tissue (VAT).
RESULTS
We enrolled 51 participants (31 gastrointestinal cancer patients and 20 controls). In cancer patients, cachexia was present in 13/31 (42%). The CSA (μm
CONCLUSIONS
We found histological alterations of SAT among gastrointestinal cancer patients and in particular significant changes in CSA, fibrosis, and inflammation when cachexia was present; the changes in histomorphological parameters of the adipocytes reflected alterations in adiposity at body composition analysis.
Identifiants
pubmed: 34939367
doi: 10.1002/jcsm.12893
pmc: PMC8818610
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-342Informations de copyright
© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Nature. 2014 Sep 4;513(7516):100-4
pubmed: 25043053
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
Clin Nutr. 2010 Apr;29(2):154-9
pubmed: 20060626
Mediators Inflamm. 2015;2015:801685
pubmed: 26504362
Eur J Pharmacol. 2011 Sep;668 Suppl 1:S87-90
pubmed: 21810420
Nat Rev Dis Primers. 2018 Jan 18;4:17105
pubmed: 29345251
Clin Nutr. 2021 Sep;40(9):5156-5161
pubmed: 34461589
Am J Nephrol. 2020;51(2):119-129
pubmed: 31910407
Nat Rev Endocrinol. 2018 Dec;15(1):9-20
pubmed: 30464312
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):40-47
pubmed: 27897393
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):37-47
pubmed: 27066317
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Curr Opin Support Palliat Care. 2010 Dec;4(4):249-53
pubmed: 20693907
Oncotarget. 2017 Aug 10;8(45):79884-79896
pubmed: 29108370
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):333-342
pubmed: 34939367
Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):442-8
pubmed: 16778574
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1045-1059
pubmed: 31273954
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1128-1142
pubmed: 31318182
Nutrition. 2012 Sep;28(9):851-5
pubmed: 22480800
BMC Cancer. 2017 Mar 14;17(1):190
pubmed: 28288584
Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1000-8
pubmed: 18713954
Cancer Med. 2021 Jul;10(13):4291-4301
pubmed: 33993635
Science. 2011 Jul 8;333(6039):233-8
pubmed: 21680814
J Cell Physiol. 2018 Jan;234(1):13-22
pubmed: 30078199
Nat Med. 2020 Aug;26(8):1264-1270
pubmed: 32661391
Clin Nutr. 2021 Jun;40(6):4037-4042
pubmed: 33676774